With the MHRA currently developing a new framework for point-of-care manufacturing, whilst also overseeing the biggest overhaul of clinical trial regulation in 20 years, this event will be an opportunity to explore what these forthcoming changes will mean for the advanced therapies and vaccines sectors in Scotland and the wider UK. Through a mixture of educational talks and interactive discussions, we’ll explore together how our community can capitalise on the opportunities that this updated regulatory environment presents.

About the Scottish Advanced Therapies and Vaccines Network
Coordinated by the Cell and Gene Therapy Catapult, and supported by Scottish Enterprise, the Network fosters collaboration and supports growth across the advanced therapy and vaccine industries in Scotland and beyond, by facilitating opportunities for academic, NHS, and industry experts to connect, exchange knowledge and tackle challenges together.

Who should attend?

• Industry professionals/investors with an interest in supporting growth in the advanced therapy/vaccine sectors in Scotland

• Academics involved in advanced therapy and/or vaccine research

• Government officials/policy makers/regulators/healthcare providers with an interest in advanced therapies/vaccines